R-CHOP Therapy Cannot Overcome CD5 Positive Non-GCB Subtype of DLBCL

Introduction: There are various poor prognosis factors in diffuse large B cell lymphoma (DLBCL). CD5 positive (CD5+) is estimated as one of the poor prognosis markers in DLBCL. CD5+DLBCL is completely distinguished from CLL or Mantle cell lymphoma, and de Novo CD5+DLBCL is related to a high incidence of cytogenetic abnormalities of 8p21 and 11q13. In many cases, CD5+DLBCL is associated with an aggressive clinical status and advanced stages. Several chromosomal studies have demonstrated the gene expression was similar to non-GCB type of DLBCL. In the clinical phase, it is easy to express chemo-resistance and CNS invasion. However, the clear characterization and mechanisms of chemo-resistance have not been demonstrated yet. In this study, we examined our previous CD5+DLBCL patients in our institute, then evaluated the prognosis and clinical characteristics regarding GCB or non GCB type.